Eli Lilly didn’t discover orexins. GLP-1 wasn’t theirs either; they licensed the mechanism, scaled it, and Mounjaro crossed $5 billion in revenue in its first full year. What they do is spot a maturing drug class, write a check before consensus forms, and dominate commercialization. That’s the tirzepatide story. It looks like the orexin story is next.
Lilly’s latest acquisition (target undisclosed) drops the company into a CNS drug class that’s been quietly building momentum for years. Orexin receptor antagonists — Merck’s suvorexant, Eisai’s lemborexant — already have insomnia approvals. The real prize is on the agonist side: orexin-2 receptor agonists for narcolepsy type 1, a condition where orexin-producing neurons are lost. No approved drug currently targets orexin deficiency directly.
Narcolepsy type 1 is chronically underdiagnosed and managed today with stimulants and sodium oxybate — blunt instruments with serious tolerability profiles. An orexin agonist that actually restores physiological wakefulness is a different product category entirely.
Lilly knows what a platform looks like. GLP-1 taught them that a mechanism, not a molecule, is the asset. Orexins fit the same template: one receptor family, multiple indications — sleep disorders, cognitive function, potentially metabolic disease.
The acquisition signals Lilly isn’t interested in being a fast-follower forever. Merck and Eisai already hold the antagonist approvals. Narcolepsy has no approved agonist yet.
Diana Kowalski